A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.
Columbia University Irving Medical Center (CUIMC) led the multicenter study.
Researchers have proposed that Alzheimer's disease is caused by the buildup of a sticky protein called beta-amyloid. According to this 'amyloid hypothesis,' the protein forms plaques in the brain that damage and eventually destroy brain cells. Solanezumab was designed to reduce the level of soluble amyloid molecules before they aggregate.
A total of 2,129 patients with mild dementia due to Alzheimer's disease participated in the double-blind, placebo-controlled, phase 3 multicenter trial. This study was the first major Alzheimer's clinical trial to require molecular evidence of amyloid deposition in the brain for enrollment.
While the treatment did have some favorable effects, in the main measure of outcome--measured with a cognitive test called the Alzheimer's Disease Assessment Scale-cognitive subscale--the researchers did not observe any statistically significant benefit compared with placebo.
The authors suggest that while it is not certain that this particular strategy or drug could be effective, it is possible that either not enough drug was administered or that the drug needs to be administered earlier in the disease course.
In other studies ongoing at CUIMC, solanezumab is being evaluated in presymptomatic patients at risk of Alzheimer's disease. Other Alzheimer's drugs are also in development and being tested at higher doses.
"Although we are disappointed that this particular drug did not prove successful, the field is benefiting from each study," says lead author Lawrence Honig, MD, PhD, professor of neurology at CUIMC. "There is hope that one of the newer ongoing studies may result in an effective treatment for slowing the course of Alzheimer's disease."
The results of this study were first released in late 2016 at the international Clinical Trials on Alzheimer's Disease meeting in San Diego.
The study is titled, 'Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.'
Additional authors are Bruno Vellas, M.D., Michael Woodward, M.D., Merc. Boada, M.D., Ph.D., Roger Bullock, M.D., Michael Borrie, M.B., Ch.B., Klaus Hager, M.D., Niels Andreasen, M.D., Ph.D., Elio Scarpini, M.D., Hong Liu Seifert, Ph.D., Michael Case, M.S., Robert A. Dean, M.D., Ph.D., Ann Hake, M.D., Karen Sundell, B.S., Vicki Poole Hoffmann, Pharm.D., Christopher Carlson, Ph.D., Rashna Khanna, M.D., Mark Mintun, M.D., Ronald DeMattos, Ph.D., Katherine J. Selzler, Ph.D., and Eric Siemers, M.D. Their affiliations are listed in the appendix of the paper.
The study was designed and funded by Eli Lilly and Company.
Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast.
For more information, visit cumc.columbia.edu or columbiadoctors.org.
Lucky Tran | EurekAlert!
Live probiotics can re-balance the gut microbiome and modify immune system response
20.11.2018 | Symprove
Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University
Max Planck researchers revel the nano-structure of molecular trains and the reason for smooth transport in cellular antennas.
Moving around, sensing the extracellular environment, and signaling to other cells are important for a cell to function properly. Responsible for those tasks...
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
19.11.2018 | Event News
09.11.2018 | Event News
06.11.2018 | Event News
20.11.2018 | Life Sciences
20.11.2018 | Life Sciences
20.11.2018 | Physics and Astronomy